New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
09:21 EDTALKS, BIIBAlkermes issued patent for fumarate pro-drug, says Citigroup
Citigroup notes that Alkermes (ALKS) was issued a United States patent for its pro-drug of mono-methyl fumarate, the active ingredient in Biogen's (BIIB) Tecfidera. Citi views the patent as supporting the regulatory potential of ALKS 8700, and notes the drug is a long-term threat to Tecfidera. The firm says Phase 1 data expected by year-end 2014 could be meaningful and keeps a Buy rating on Alkermes with a $60 price target.
News For ALKS;BIIB From The Last 14 Days
Check below for free stories on ALKS;BIIB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
09:48 EDTALKSAlkermes management to meet with Leerink
Meetings to be held in Canada October 6-7 hosted by Leerink.
07:26 EDTBIIBInforma Business Information to hold a conference
Subscribe for More Information
September 24, 2014
09:52 EDTALKSAlkermes expects to receive $59M in connection to Acorda-Civitas deal
Subscribe for More Information
September 22, 2014
07:21 EDTBIIBEBD Group to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use